Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Synergic Effect of Trimebutine Combined with Mosapride on Gastrointestinal Dysfunction and Visceral Pain Induced in Stress Models

  • Received : 2010.08.25
  • Accepted : 2010.09.18
  • Published : 2011.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was undertaken to determine whether combined treatment with prokinetic trimebutine and mosapride has a synergic effect on gastrointestinal motility and visceral pain associated with gastrointestinal dysfunction. To develop effective gastroprokinetic agents with greater potencies than trimebutine or mosapride for the treatment of gastrointestinal tract disease, a mixture of trimebutine and mosapride was designed and prepared. In the present study, treatment with trimebutine alone showed a dose-dependent effect on propelling movements of normal small and large intestine in mice, whereas mosapride effected only small intestine motility. Co-administration of trimebutine with mosapride, a well-established prokinetic drug, produced a synergistic influence on normal small intestine motility, but demonstrated an unclear effect on large intestine motility, with a slight tendency to reduce the propelling time. In a stress model, the small and large intestine motilities were significantly decreased. The reduction of intestine motility was restored to a normal level and the restoring effect was more pronounced in the combined treatment with trimebutine plus mosapride than treatment with trimebutine or mosapride alone. Furthermore, treatment with trimebutine plus mosapride significantly decreased acute visceral pain which was not controlled by trimebutine or mosapride alone. These data suggest that combination therapy with trimebutine plus mosapride has a synergic effect on small and large intestine motility and visceral pain control in gastrointestinal disorders.

Keywords

References

  1. Boyle, G., Mounsey, A. and Crowell, K. (2009) Clinical inquiries: what is the role of prokinetic agents for constipation? J. Fam. Pract. 58, 220d-220f.
  2. Chicella, M. F., Batres, L. A., Heesters, M. S. and Dice, J. E. (2005) Prokinetic drug therapy in children: a review of current options. Ann. Pharmacother. 39, 706-711. https://doi.org/10.1345/aph.1E411
  3. Chua, A. S., Bekkering, M., Rovati, L. C. and Keeling, P. W. (1994) Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann. N. Y. Acad. Sci. 713, 451-453. https://doi.org/10.1111/j.1749-6632.1994.tb44124.x
  4. Curran, M. P. and Robinson, D. M. (2008) Mosapride in gastrointestinal disorders. Drugs 68, 981-991. https://doi.org/10.2165/00003495-200868070-00007
  5. Delco, M. L., Nieto, J. E., Craigmill, A. L., Stanley, S. D. and Snyder, J. R. (2007) Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses. Vet. Ther. 8, 77-87.
  6. Delvaux, M. and Wingate, D. (1997) Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J. Int. Med. Res. 25, 225-246.
  7. Dubinsky, B., Gebre-Mariam, S., Capetola, R. J. and Rosenthale, M. E. (1987) The antialgesic drugs: human therapeutic correlates of their potency in laboratory animal models of hyperalgesia. Agents Actions 20, 50-60. https://doi.org/10.1007/BF01965625
  8. Greenwood, B. and Davison, J. S. (1987) The relationship between gastrointestinal motility and secretion. Am. J. Physiol. 252, G1-7.
  9. Hawkyard, C. V. and Koerner, R. J. (2007) The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J. Antimicrob. Chemother. 59, 347-358. https://doi.org/10.1093/jac/dkl537
  10. Holzer, P. (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci. Lett. 361, 192-195. https://doi.org/10.1016/j.neulet.2003.12.004
  11. Kii, Y., Nakatsuji, K., Nose, I., Yabuuchi, M., Mizuki, Y. and Ito, T. (2001) Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol. Toxicol. 89, 96-103. https://doi.org/10.1034/j.1600-0773.2001.d01-142.x
  12. Koop, H., Monnikes, H., Koop, I., Dionysius, J., Schwarz, C. and Arnold, R. (1986) Effect of the prokinetic drug cisapride on gastrointestinal hormone release. Scand. J. Gastroenterol. 21, 907-913. https://doi.org/10.3109/00365528608996394
  13. Kountouras, J., Chatzopoulos, D., Zavos, C., Boura, P., Venizelos, J. and Kalis, A. (2002) Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology 49, 193-197.
  14. Luttecke, K. (1978) A trial of trimebutine in spastic colon. J. Int. Med. Res. 6, 86-88. https://doi.org/10.1177/030006057800600202
  15. Matsue, T., Yamato, S. and Umeda, N. (1990) Mechanism of action of trimebutine maleate on gastro-colic reflex in patients with irritable bowel syndrome. Nippon Heikatsukin Gakkai Zasshi 26, 89-92.
  16. Mine, Y., Yoshikawa, T., Oku, S., Nagai, R., Yoshida, N. and Hosoki, K. (1997) Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J. Pharmacol. Exp. Ther. 283, 1000-1008.
  17. Nosaka, K., Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984) Effects of trimebutine maleate (TM-906) on the gastrointestinal motility in anesthetized dogs. Nippon Heikatsukin Gakkai Zasshi 20, 407-412. https://doi.org/10.1540/jsmr1965.20.407
  18. Odaka, T., Suzuki, T., Seza, A., Yamaguchi, T. and Saisho, H. (2006) Serotonin 5- HT4 receptor agonist (mosapride citrate). Nippon Rinsho 64, 1491-1494.
  19. Reynolds, J. C. and Putnam, P. E. (1992) Prokinetic agents. Gastroenterol. Clin. North Am. 21, 567-596.
  20. Roman, F. J., Lanet, S., Hamon, J., Brunelle, G., Maurin, A., Champeroux, P., Richard, S., Alessandri, N. and Gola, M. (1999) Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J. Pharmacol. Exp. Ther. 289, 1391-1397.
  21. Sakurai-Yamashita, Y., Takada, K., Takemura, K., Yamashita, K., Enjoji, A., Kanematsu, T. and Taniyama, K. (1999) Ability of mosapride to bind to 5-HT4 receptor in the human stomach. Jpn. J. Pharmacol. 79, 493-496. https://doi.org/10.1254/jjp.79.493
  22. Shimada, T., Kurachi, Y., Terano, A., Hamada, E. and Sugimoto, T. (1990) Trimebutine maleate has inhibitory effects on the voltage-dependent Ca2+ inward current and other membrane currents in intestinal smooth muscle cells. Gastroenterol. Jpn. 25, 175-179.
  23. Takagi, K. and Okabe, S. (1968) The effects of drugs on the production and recovery processes of the stress ulcer. Jpn. J. Pharmacol. 18, 9-18. https://doi.org/10.1254/jjp.18.9
  24. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984a) Effects of trimebutine maleate (TM-906) on the smooth muscles of isolated guinea pig gallbladder. Jpn. J. Pharmacol. 35, 439-443. https://doi.org/10.1254/jjp.35.439
  25. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984b) Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated guinea pig colon. Jpn. J. Pharmacol. 34, 177-181. https://doi.org/10.1254/jjp.34.177
  26. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1986) Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated duodenum and ileum in both guinea pigs and rabbits. Jpn. J. Pharmacol. 40, 13-20. https://doi.org/10.1254/jjp.40.13
  27. Tanaka, M. (1998) Gastric ulcer, motility, and trimebutine. J. Gastroenterol. 33, 916-917. https://doi.org/10.1007/s005350050201
  28. Uchiyama, M., Iwafuchi, M., Yagi, M., Iinuma, Y., Kanada, S., Ohtaki, M. and Homma, S. (2000) Effects of trimebutine on intestinal motility after massive small bowel resection. J. Smooth. Muscle. Res. 36, 117-126. https://doi.org/10.1540/jsmr.36.117
  29. Washabau, R. J. (2003) Gastrointestinal motility disorders and gastrointestinal prokinetic therapy. Vet. Clin. North Am. Small Anim. Pract. 33, 1007-1028, vi. https://doi.org/10.1016/S0195-5616(03)00076-7
  30. Wingate, D., Hongo, M., Kellow, J., Lindberg, G. and Smout, A. (2002) Disorders of gastrointestinal motility: towards a new classification. J. Gastroenterol. Hepatol. 17(Suppl), S1-14. https://doi.org/10.1046/j.1440-1746.17.s1.7.x
  31. Yoshida, N., Ito, T., Karasawa, T. and Itoh, Z. (1991) AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J. Pharmacol. Exp. Ther. 257, 781-787.
  32. Yoshida, N., Omoya, H., Kato, S. and Ito, T. (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 43, 1078-1083.
  33. Zenilman, M. E. (1993) Origin and control of gastrointestinal motility. Surg. Clin. North. Am. 73, 1081-1099.
  34. Zhang, H. Q., Zhou, C. H. and Wu, Y. Q. (2005) Effect of emodin on small intestinal peristalsis of mice and relevant mechanism. World J. Gastroenterol. 11, 3147-3150. https://doi.org/10.3748/wjg.v11.i20.3147